TScan Therapeutics TCRX Institutional Ownership

Ownership Summary

TScan Therapeutics, Inc. (NASDAQ:TCRX) has 60 institutional investors that have filed 13F reports for the period ending March 2026.

• They owned 25.0% of outstanding stock in March 2026, up from 23.7% the prior quarter.
• They increased total shares held in TScan Therapeutics by 16.84% from last quarter, and the number of investors in TCRX decreased 35.48% annually.
• During the quarter, 26 of these 60 funds increased positions in TCRX, 21 reduced exposure, and 13 held steady.
• Combined, these investors held 32.5Mn shares in TCRX for March 2026, up by 4.69Mn shares quarter on quarter, and down 8.2Mn shares year over year.
• Lynx1 Capital Management LP is the top holder of TScan Therapeutics as of March 31, 2026, with 8.02Mn shares representing 6.17% of outstanding stock.
• The most significant purchases of TCRX for the quarter ending March 2026 came from VANGUARD CAPITAL MANAGEMENT LLC (2.15Mn), MILLENNIUM MANAGEMENT LLC (1.06Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (620.2K), TWO SIGMA INVESTMENTS, LP (557.83K), BVF INC/IL (338.22K).
• The largest sales of TCRX for the quarter ending March 2026 came from Aberdeen Group plc (867.22K), JANE STREET GROUP, LLC (243.86K), XTX Topco Ltd (158.28K), Goldman Sachs Group Inc (136.54K), MARSHALL WACE, LLP (101.89K).
• Per Business Quant, the top 10 investors in TCRX for the quarter ending March 2026 include Lynx1 Capital Management LP (8.02Mn), BVF INC/IL (5.56Mn), BAKER BROS. ADVISORS LP (2.78Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.15Mn), BlackRock, Inc. (1.84Mn), MILLENNIUM MANAGEMENT LLC (1.46Mn), RENAISSANCE TECHNOLOGIES LLC (1.36Mn), Deer Management Co. LLC (1.25Mn), TWO SIGMA INVESTMENTS, LP (1.21Mn), Aberdeen Group plc (918.02K).